Vertex Pharmaceuticals VRTX
NASDAQ VRTX
$534.88 +10.36 (+1.98%)
As of: Oct 22, 2026 · 1:04 PM EDT

Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017)

Updated

Vertex Pharmaceuticals (VRTX) recorded Short-Term Debt repayments of $300 million in FY2017.

Analysis

Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,166.82 Bn 1,135.41 Bn 19.71 Bn -
2 Johnson & Johnson 644.52 Bn 564.38 Bn 17.30 Bn 6.63 Bn
3 AbbVie 501.88 Bn 474.99 Bn 12.70 Bn -
4 Merck 358.72 Bn 313.10 Bn 12.21 Bn -
5 Novartis Ag 302.27 Bn 266.26 Bn 11.24 Bn -
6 Astrazeneca 267.62 Bn 241.31 Bn 12.86 Bn -
7 Amgen 241.67 Bn 197.07 Bn 7.24 Bn -
8 Gilead Sciences 193.09 Bn 167.28 Bn 6.22 Bn -
9 Pfizer 171.60 Bn 118.24 Bn 10.94 Bn -
10 Vertex Pharmaceuticals 135.93 Bn 107.94 Bn 2.84 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 300.00 Mn
API Access

Vertex Pharmaceuticals Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=VRTX&period=max&api_key=YOUR_API_KEY